Regen BioPharma Business Summary

Regen BioPharma Inc (RGBP) is a development-stage biotechnology company that generates revenue primarily through the strategic licensing of its intellectual property (IP) portfolio, which includes upfront fees, milestone payments, and royalties ranging from 4% to 5% on net sales. The company’s business is segmented into two primary areas: immunotherapy, which focuses on modulating the NR2F6 immune checkpoint for oncology and autoimmune applications (e.g., DuraCAR and dCellVax), and regenerative medicine, centered on stem cell-derived therapies like HemaXellerate for bone marrow repair. Positioned as a micro-cap innovator in the autologous cell therapy space, Regen BioPharma competes with firms such as IN8bio, Lipella Pharmaceuticals, and International Stem Cell, distinguishing itself through its specialized focus on NR2F6 gene-silencing and small molecule inhibitors. The leadership team is anchored by Chairman and CEO David Raymond Koos, Ph.D., who also serves as the company’s CFO and President; Koos brings over 30 years of experience in investment banking and venture capital to the firm's lean operational structure. Scientific direction is supported by a robust Scientific Advisory Board featuring prominent researchers such as Dr. Ravinder Reddy and Dr. Mohammad Haris from the University of Pennsylvania, who provide expertise in CAR-T cell therapy and metabolic imaging. Major shareholders include David Koos and Harry Lander, reflecting a high degree of insider ownership as the company advances its lead candidates through Phase I/II clinical trials and seeks Orphan Drug Designations to enhance market exclusivity.